Pooled results from three clinical trials of myeloprotection therapy trilaciclib (Cosela) in extensive-stage small cell lung cancer (ES-SCLC)
Results show trilaciclib, an IV CDK4/6 inhibitor, prior to chemotherapy resulted in significant decreases in most measures of multilineage chemotherapy-induced myelosuppression, with a reduction in the incidence of chemotherapy-related haematologic adverse events vs placebo.
Source:
Biospace Inc.